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Abstract. Ximenynic acid is a conjugated enyne fatty acid, 
which is currently of interest due to its anti‑inflammatory 
activity. Due to the association between inflammation 
and cancer, the present study was designed to investigate 
the anti‑cancer activity of ximenynic acid in the HepG2 
human hepatoma cell line and the underlying mechanisms. 
The current study demonstrated the anti‑proliferation and 
pro‑apoptosis activities of ximenynic acid by cell viability 
assay and f low cytometry analysis. The expression of 
anti‑apoptosis protein silent information regulator T1 (SIRT1) 
was significantly suppressed by ximenynic acid. Furthermore, 
ximenynic acid blocked G1/S phase transition by inhibiting 
the protein expression of the cell cycle‑associated protein 
general control of amino acid synthesis yeast homolog like 2 
(GCN5L2), and the mRNA expression of cyclin D3 and cyclin 
E1. Furthermore, ximenynic acid suppressed the expression of 
angiogenesis‑associated genes, including vascular endothelial 
growth factor (VEGF)‑B and VEGF‑C. Finally, ximenynic 
acid significantly inhibited the expression of cyclooxygenase‑1 
(COX‑1) mRNA and protein, however COX‑2 expression 
was not reduced. The results of the present study suggested 
that ximenynic acid may inhibit growth of HepG2 cells by 
selective inhibition of COX‑1 expression, which leads to cell 
cycle arrest, and alters the apoptosis pathway and expression 
of angiogenic factors. The current study aimed to investigate 
whether ximenynic acid might be developed as novel anti‑
cancer agent.
Introduction
Ximenynic acid (also termed santalbic acid) is a conjugated 
enyne fatty acid that predominantly exists in the seed oil of the 
Santalaceae, Olacaceae, and Opiliaceae families (1). Previous 
studies demonstrated that ximenynic acid has antibacte‑
rial (2,3), antifungal and anti‑inflammatory activities (3,4). 
Among these properties, the anti‑inflammatory activity of 
ximenynic acid has been widely studied.
The anti‑inflammatory activity of ximenynic acid has been 
reported since the 1980s. Nugteren and Christ‑Hazelhof (5) 
demonstrated that ximenynic acid inhibits the activity of 
COXs in the sheep vesicular gland microsomes (5). In rat 
peritoneal leukocytes, ximenynic acid inhibited the phos‑
pholipase activity and the production of inflammatory 
factors, including thromboxane B2, 6‑ketoprostaglandin F1α 
and leukotriene B4 (4). It was observed that the levels of 
leukotriene B4, thromboxane B2, prostaglandin F2α and 
prostaglandin E2 (PGE2) in the sandalwood seed oil feeding 
group, which contains a high percentage of ximenynic acid, 
were significantly lower in rat liver and plasma compared with 
soybean oil and safflower oil feeding groups after feeding 
for 8 weeks (6). These reports suggested that ximenynic acid 
exerts anti‑inflammatory activity by affecting the metabolism 
of arachidonic acid.
Arachidonic acid metabolism pathways, induced by 
lipoxygenase, cyclooxygenase (COX) and cytochrome P450, 
are important for regulating the inflammatory response (7), 
and they generate several eicosanoid products, including 
leukotrienes and prostanoids, which are closely associated 
with the inflammatory response. It is established that lipoxy‑
genase, COX and cytochrome P450 are key targets in various 
pathologies, including pain, cardiovascular disease, inflamma‑
tion and cancer (7). The eicosanoids metabolism induced by 
COX has been previously reported to be involved in various 
types of cancer (8). Most nonsteroidal anti‑inflammatory drugs 
(NSAIDs) are inhibitors of COXs, and they can reduce the 
risk of cancer, which was supported by preclinical and clinical 
studies (9). Furthermore, many natural and synthetic acetylenic 
acids exert inhibitory effects on cancer cells by suppressing key 
enzymes of the arachidonic acid metabolism pathways (10).
There are two common types of COX: COX‑1 and COX‑2. 
Although COX‑2 inhibitors for treating cancer have been a 
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research focus for many years, suppression of COX‑1 was also 
demonstrated to exhibit anti‑cancer properties (11,12), and alter 
the distribution of cell cycle (13) and effect angiogenesis (14). 
Furthermore, inhibition of angiogenesis and arrest of the cell 
cycle in oncocytes may induce cell apoptosis (15,16).
There are few reports that directly demonstrate the 
anti‑cancer activity of ximenynic acid, thus, it was hypoth‑
esized that ximenynic acid may have antitumor properties 
through inhibition of COX activation. The current study inves‑
tigated the anti‑cancer activity of ximenynic acid in HepG2, 
and analyzed the underlying mechanism through determining 
its effects on cell cycle, angiogenesis and COXs pathways.
Materials and methods
Fatty acid preparation. Ximenynic acid was obtained (99.5% 
purity) from the seed oil of Santalum spicatum by low 
temperature recrystallization, as described previously (17). 
Oleic acid (Sigma‑Aldrich; Merck Millipore, Darmstadt, 
Germany) was selected as the non‑alkynyl‑fatty acid control 
for its similar structure to ximenynic acid. All other chemicals 
were purchased commercially as analytical grade reagents.
Cell culture and cell treatment. HepG2 human hepatoma cell 
line was obtained from the Type Culture Collection of the 
Chinese Academy of Sciences (Shanghai, China). Cells were 
grown in high glucose Dulbecco's modified Eagle's medium 
(DMEM; Hyclone; GE Healthcare Life Sciences, Logan, 
UT, USA) supplemented with 110 mg/l sodium pyruvate, 
4 mM L‑glutamine, 10% fetal bovine serum (Biowest, Nuaillé, 
France), 10 mM HEPES (Corning Incorporated, Corning, NY, 
USA), 100 U/ml penicillin and 0.1 mg/ml streptomycin at 37˚C 
in a humidified incubator with 5% CO2. The medium was 
changed every 2 days. Cells were passaged when they reached 
70‑80% confluence, and the culture medium was changed 
1 day before.
Cells were seeded overnight in standard medium and 
then change to serum‑free medium supplemented with 
1% insulin‑transferrin‑selenium (ITS; Invitrogen; Thermo 
Fisher Scientific, Inc., Waltham, MA, USA), 0.1 mg/ml fatty 
acid‑free bovine serum albumin (BSA; MP Biomedicals, 
LLC, Santa Ana, CA, USA) for synchronizing cell cycle 
division. After 24 h serum starvation, cells were incubated 
in experimental media for indicated times. The experimental 
media was DMEM supplemented with 1% ITS, 0.1 mg/ml 
BSA and various concentrations of ximenynic acid or oleic 
acid with a molar ratio of 4:1 to BSA. Cells treated with 
medium not containing fatty acids were termed the vehicle 
control group.
Cell viability assay. Cells were cultured in 96‑well plates over‑
night with ~1500 cells/well. After serum‑starving for 24 h, 
serum‑free medium was removed and ximenynic acid or oleic 
acid at 25, 50, 100 and 150 µM were added to the cells. After 
72 h incubation, the media were replaced with serum‑free 
medium diluted methyl thiazolyl tetrazolium (MTT; Amresco, 
LLC, Solon, OH, USA) solution (5 mg/ml) and incubated at 
37˚C for 4 h. Subsequently, MTT medium was removed and 
the cells were dissolved with dimethyl sulfoxide followed by 
detection of absorption at 595 nm with the Bio‑Rad iMark 
Microplate Absorbance Reader (Bio‑Rad Laboratories, Inc., 
Hercules, CA, USA).
Flow cytometry analysis. Cell cycle distribution was analyzed 
by propidium iodide (PI) staining. Cells were seeded in the 
6‑well plates overnight, and then incubated with serum‑free 
media containing 50 or 150 µM ximenynic acid or oleic acid 
for 24 h and 36 h following rinsing with phosphate‑buffered 
saline (PBS). The harvested cells were slowly fixed in 
pre‑chilled 70% ethanol following washing with PBS. The 
fixed cells were incubated at ‑20˚C overnight. Subsequently 
to rinsing with PBS, cells were re‑suspended with PI solution 
from the Cell Cycle Staining kit [CCS012; Multi Sciences 
(Lianke) Biotech Co., Ltd., Hangzhou, China] and incubated in 
a dark at room temperature for 30 min. Cell cycle distribution 
was then analyzed using BD FACSCalibur (Becton Dickinson, 
USA).
Cell apoptosis was analyzed with Annexin V‑FITC (fluo‑
rescein isothiocyanate) and PI kit (Multisciences, China). Cells 
were cultured in 6‑well plates overnight, and then starved 
for 24 h with serum‑free medium followed by culture with 
different concentrations of ximenynic acid or oleic acid for 
72 h. The harvested cells were gently rinsed with PBS. Cells 
were stained with Annexin V‑FITC and PI in dark for 15 min. 
The level of apoptosis was then analyzed by BD FACSCalibur 
(BD Biosciences, Franklin Lakes, NJ, USA).
Reverse transcription‑quantitative polymerase chain reac‑
tion (RT‑qPCR). Cells were seeded in 6‑well plates overnight. 
After starving for 24 h with serum‑free medium, cells were 
treated with 50 or 150 µM ximenynic acid or oleic acid for 
72 h. Total RNA was extracted by HP Total RNA kit (Omega 
Bio‑Tek, Inc., Norcross, GA, USA) according to the manufac‑
turer's protocol, and the RNA concentration was determined 
using a NanoDrop 2000 (Thermo Fisher Scientific, Inc., 
Wilmington, DE, USA). RT was performed on total RNA to 
produce cDNA with using a Transcriptor First Strand cDNA 
Synthesis kit (Roche Diagnostics, Basel, Switzerland). The 
expression of genes was analyzed by qPCR. The sequences 
of primers are presented in Table I. The qPCR analysis was 
performed using the SsoFast EvaGreen Supermix (Bio‑Rad 
Laboratories, Inc.), according to the manufacturer's protocol, 
with a CFX96™ Real Time PCR Detection System (Bio‑Rad 
Laboratories, Inc.). The qPCR program commenced with 
initial denaturation at 95˚C for 30 sec followed by 40 ampli‑
fication cycles of 95˚C for 5 sec (denaturation) and 60˚C for 
10 sec (annealing and extension). The melting curve program 
was from 65˚C to 95˚C for 5 sec with an increment rate of 
0.5˚C/sec (18). The RPLPO gene was used as the reference 
gene. Data were selected from a minimum of 3 experiments.
Western blot analysis. Cells were cultured in 100 mm dishes 
overnight and then starved with serum‑free medium for 24 h. 
After treatment with 50 or 150 µM ximenynic acid or oleic 
acid for 72 h, cells were harvested and proteins were extracted 
using cell lysis buffer supplemented with phenylmethylsul‑
fonyl fluoride (Beyotime Institute of Biotechnology, Haimen, 
China). Whole‑cell lysates were centrifuged at 20,000 x g 
at 4˚C, for 10 min to collect the supernatant. The protein 
concentration was determined by bicinchoninic acid protein 
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assay (Beyotime Institute of Biotechnology). Protein (20 µg) 
were subjected to sodium dodecyl sulfate‑polyacrylamide gel 
electrophoresis separation and transferred to polyvinylidene 
difluoride membrane (Bio‑Rad Laboratories, Inc.) for probing 
with antibodies. The antibodies for caspase‑3 (cat. no. 9662s), 
silent information regulator T1 (SIRT1; cat. no. 2496p), COX‑2 
(cat. no. 12282s), general control of amino acid synthesis 
yeast homolog like 2 (GCN5L2; cat. no. 3305p), and GAPDH 
(cat. no. 2118s) were purchased from Cell Signaling Technology, 
Inc. (Danvers, MA, USA), and COX‑1 (cat. no. ab109025) 
from Abcam (Cambridge, UK). The secondary antibodies 
were anti‑mouse IgG (cat. no. #7076) and anti‑rabbit IgG 
(cat. no. #7074) from Cell Signaling Technology, Inc. These 
antibodies were diluted in 5% BSA (1:1,000; Beyotime Institute 
of Biotechnology). The immunoreactive bands were incubated 
with the primary antibodies overnight at 4˚C, then were washed 
three times with PBS with Tween‑20 (PBST). The secondary 
antibody was incubated for 1 h at room temperature, and also 
washed three time with PBST. The protein bands were visual‑
ized using the ECL reagent (Bio‑Rad Laboratories, Inc.). The 
intensity of immunoreactive bands was analyzed by Quantity 
One software (Bio‑Rad Laboratories, Inc.). Western blotting 
data were selected from a minimum of three independent 
experiments.
Statistical analysis. Data are expressed as the mean ± standard 
deviation of three independent experiments. The significance 
of the difference between groups was analyzed by SPSS 
software version 18 (SPSS, Inc., Chicago, IL, USA) using the 
Bonferroni or Dunnett's T3 method of single factor analysis of 
variance (19). P<0.05 was considered to indicate a statistically 
significant difference.
Results
Inhibition of proliferation by ximenynic acid. HepG2 cells 
were treated with different concentrations (0‑150 µM) of 
ximenynic acid or oleic acid for 72 h, and the cell viability 





















































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Cell viability analysis of HepG2 cells with XA or OA treatment 
by methyl thiazolyl tetrazolium assay. Variation curves of cell viability by 
XA or OA treatment with different concentrations ranging from 0‑150 µM. 
Values are expressed as the mean ± standard deviation; n=3. *P<0.05 vs. the 
vehicle group. OA, oleic acid; XA, ximenynic acid.
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acid significantly inhibited the growth of HepG2 cells from 
0 to 150 µM in a dose‑dependent manner compared with 
the control group (P=0.12, 25 µM; P=0.04, 50 µM; P=0.03, 
100 µM; P=0.12, 150 µM), while oleic acid could not inhibit 
HepG2 cell growth at every concentration compared with the 
control group (Fig. 1).
Induction of HepG2 apoptosis and caspase‑3 activation by 
ximenynic acid. Considering the anti‑proliferation activity of 
ximenynic acid demonstrated in Fig. 1, it was suspected that 
ximenynic acid may also lead to apoptosis of HepG2 cells. 
Thus, the HepG2 cells were treated with ximenynic acid or 
oleic acid (50 and 150 µM) for 72 h followed by PI staining 
and flow cytometry analysis (Fig. 2A). It was observed that 
the percentage of apoptotic cells was significantly increased 
by ximenynic acid at a concentration of 150 µM in a 
dose‑dependent manner (P=0.018; Fig. 2B), and accordingly 
the percentage of live cells was significantly reduced at the 
same concentration (P=0.004; Fig. 2C) compared with the 
vehicle control group. In the oleic acid group, the percentage 
of apoptotic cells and living cells was not significantly 
different compared with the control group (Fig. 2B and C). 
The anti‑cancer activity of 150 µM ximenynic acid was 
greater than that of oleic acid.
The degradation of pro‑caspase‑3 protein occurs during 
the process of cell apoptosis, which results in protein cleavage 
into several fragments (20) and indirectly induces a decrease 
in the pro‑protein. The cleaved caspase‑3 (17 KDa) was 
not detected in the ximenynic acid group, however western 
blot analysis demonstrated that the level of pro‑caspase‑3 
(35 KDa) was significantly decreased by 150 µM ximenynic 
acid compared with the vehicle control (P=0.001, P<0.05; 
Fig. 2D). Together, flow cytometry and western blot analyses 
indicated that ximenynic acid promotes apoptosis of HepG2 
cells in a dose‑dependent manner, and was more effective 
than oleic acid.
Effect of ximenynic acid on SIRT1 protein expression. The 
upstream signals that mediate the effect of ximenynic acid on 
apoptosis remain unclear. SIRT1 is a NAD‑dependent deacet‑
ylase that inhibits apoptosis by downregulating transcriptional 
activity of p53 (21). In addition, SIRT1 silencing induces 
activation of caspase‑3, indicating it is a downstream target 
of SIRT1 (22). The current study demonstrated that SIRT1 
Figure 2. Ximenynic acid induced apoptosis of HepG2 cells. (A) Cell apoptosis analysis of HepG2 cells treated with ximenynic acid or oleic acid at different 
concentrations by flow cytometry. (B) Levels of early apoptosis cells in the different groups. (C) Levels of alive cells in the different groups. (D) Caspase‑3 
protein expression in different groups. O50 and O150 groups were treated with oleic acid at 50 and 150 µM, respectively. X50 and X150 groups were treated 
with ximenynic acid at 50 and 150 µM, respectively. Values are expressed as the means ± standard deviation; n=3. *P<0.05 vs. the vehicle group.
Figure 3. The expression of fold change of SIRT1 protein in HepG2 cells fol‑
lowing fatty acids treatment. Cells were incubated with ximenynic acid or 
oleic acid at two concentrations (50 and 150 µM) and with vehicle medium 
for 72 h. O50 and O150 groups were treated with oleic acid at 50 and 150 µM, 
respectively. X50 and X150 groups were treated with ximenynic acid at 50 and 
150 µM, respectively. Data are presented as the mean ± standard deviation; 
n=3. *P<0.05 vs. the vehicle group. SIRT1, silent information regulator T1. 
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protein expression was significantly reduced by 150 µM xime‑
nynic acid compared with the vehicle control group (P=0.013, 
50 µM; P=0.019, 150 µM), whereas there was no significant 
difference in the oleic acid groups compared with vehicle 
(Fig. 3). These results indicate that ximenynic acid‑induced 
apoptosis is associated with SIRT1 inhibition in HepG2 cells.
Cell cycle changes and expression variation of cell cycle‑asso‑
ciated genes and proteins in HepG2 cells. Cell cycle arrest 
in G1/S transition can induce cancer cell apoptosis (16). The 
current study investigated whether ximenynic acid affects the 
cell cycle distribution. After treatment with ximenynic acid for 
24 or 36 h, the cell cycle distributions of HepG2 cells were 
observably changed (Fig. 4A‑C). The percentage of cells in 
G0/G1 phase was significantly increased in the ximenynic 
acid groups (P=0.002, 24 h, 50 µM; P=0.001, 24 h, 150 µM; 
P=0.001, 36 h, 50 µM; P=0.001, 36 h, 150 µM; Fig. 4A), and 
significantly decreased in S phase (P=0.002, 24 h, 50 µM; 
P=0.001, 24 h, 150 µM; P=0.001, 36 h, 50 µM; P=0.001, 36 h, 
150 µM; Fig. 4B) and G2/M phase (P=0.014, 24 h, 50 µM; 
P=0.001, 24 h, 150 µM; P=0.001, 36 h, 50 µM; P=0.005, 36 h, 
150 µM; Fig. 4C) compared with the vehicle control group 
in a dose‑ and time‑dependent manner. The structures of 
ximenynic acid and oleic acid are similar, however, oleic acid 
did not observably alter the cell cycle distributions of HepG2 
cells at 50 or 150 µM (Fig. 4A‑C). These results indicate that 
ximenynic acid change the cell cycle distribution of HepG2 
cells depending on the dose and duration of ximenynic acid 
treatment.
To understand whether ximenynic acid affects the expres‑
sion of cell cycle‑associated genes in HepG2 cells, qPCR 
analysis was performed to determine the expression variation 
of cyclin genes, including cyclin E1 (CCNE1) and cyclin D3 
(CCND3). After treatment for 36 h, the mRNA levels of CCNE1 
and CCND3 were significantly decreased in the50 and 150 µM 
ximenynic acid group compared with the vehicle control group 
(CCNE1, P=0.001; CCND3, P=0.043; Fig. 4D and E), and its 
inhibitory effect on CCND3 and CCNE1 was stronger than 
oleic acid.
GCN5L2 (also termed lysine acetyltransferase 2A) is a 
typical histone acetyltransferase (HAT), which promotes 
cell cycle progression by acetylation and deacetylation 
of histones (23). The expression of GCN5L2 protein was 
significantly downregulated in the 150 µM ximenynic acid 
group compared with the vehicle control group (P=0.026; 
Fig. 4F).
Effect of ximenynic acid on cyclooxygenase pathway. COX‑1 
and COX‑2 mRNA and protein were demonstrated to be 
expressed in the HepG2 cells (Fig. 5). After serum starvation 
for 24 h, HepG2 cells were incubated with fatty acids for 
72 h. Although COX‑2 protein expression was significantly 
increased in oleic acid group at 50 µM (P=0.01, P<0.05), it 
was not changed in the ximenynic acid group compared 
with the vehicle control group (Fig. 5A). These results were 
largely in keeping with the COX‑2 gene expression of PTGS2 
[prostaglandin‑endoperoxide synthase 2 (PTGS2)] in HepG2 
(Fig. 5C).
Figure 4. The effects of ximenynic acid or oleic acid treatment on cell cycle distribution and expression of cell cycle related genes and protein. Flow cytometry 
analysis of HepG2 cells treated with vehicle, ximenynic acid or oleic acid by staining with propidium iodide. Variations of cell cycle distributions in the 
(A) G0/G1, (B) S, and (C) G2/M phases were determined. Expression fold changes of (D) CCNE1 and (E) CCND3 mRNA after 36 h fatty acid treatment were 
measured by reverse transcription‑polymerase chain reaction. (F) Differential expression of GCN5L2 protein in different fatty acids treatment groups were 
determined by western blot analysis. O50 and O150 groups were treated with oleic acid at 50 and 150 µM, respectively. X50 and X150 groups were treated with 
ximenynic acid at 50 and 150 µM, respectively. Data are presented as the mean ± standard deviation; n=3. *P<0.05 vs. the 24 h vehicle group; #P<0.05 vs. the 
36 h vehicle group. CCNE1, cyclin E1; CCND3, cyclin D3; GCN5L2,  general control of amino acid synthesis yeast homolog like 2.
  A   B   C
  D   E   F
CAI et al:  THE ANTI‑CANCER ACTIVITY OF XIMENYNIC ACID IN HEPG2 CELLS6
Unexpectedly, compared with COX‑2, ximenynic acid 
exerted a greater effect on COX‑1, with PTGS1 mRNA 
(P=0.009, 50 µM; P=0.001, 150 µM; Fig. 5D) and COX‑1 
protein (P=0.005, 50 µM; P=0.001, 150 µM; Fig. 5B) levels 
significantly decreased by 50 to 150 µM ximenynic acid 
compared with the vehicle control group, whereas PTGS1 
levels were significantly increased by oleic acid treatment at the 
concentrations of 50 and 150 µM (P=0.001, 50 µM; P=0.001, 
150 µM; Fig. 5D). These results indicate that ximenynic acid 
selectively inhibits COX‑1 expression.
PGE2 is the product of arachidonic acid metabolism 
by COXs (24). Prostaglandin E receptor 2 (EP2) a prosta‑
glandin E receptor 4 (EP4) are PGE2 receptors involved in 
various physiological and pathophysiological processes (25). 
EP2 and EP4 mRNAs were significantly downregulated 
in the 150 µM ximenynic acid group compared with the 
vehicle control (EP2, P=0.03; EP4, P=0.001), while they were 
unchanged by oleic acid (Fig. 5E and F). It was indicated 
that the inhibitory effect of ximenynic acid on EP2 and EP4 
mRNA levels was more effective than that of oleic acid.
Effect of ximenynic acid on angiogenesis pathways. Vascular 
endothelial growth factor (VEGF)‑B and VEGF‑C are two 
members of the VEGF family that induce angiogenesis and 
inhibit apoptosis (26). The VEGF‑B and VEGF‑C mRNA 
levels were significantly decreased in the 50 and 150 µM 
Figure 5. Influence of ximenynic acid or oleic acid treatments on the cyclooxygenase pathway. (A) PTGS2 and (B) PTGS1 mRNA expression levels in dif‑
ferent treatment groups. (C) COX‑1 and (D) COX‑2 proteins expression levels in different treatment groups.  (E) EP2 and (F) EP4 mRNA expression levels 
in different groups. O50 and O150 groups were treated with oleic acid at 50 and 150 µM, respectively. X50 and X150 groups were treated with ximenynic 
acid at 50 and 150 µM, respectively. Data are presented as the mean ± standard deviation; n=3. *P<0.05 vs. the vehicle group. COX, cyclooxygenase; PTGS, 
prostaglandin‑endoperoxide synthase; EP, prostaglandin E receptor.
  A   B
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ximenynic acid groups compared with the vehicle control 
group (P<0.05) and oleic acid (P<0.05) groups (VEGF‑B: 
P=0.001, 50 µM; P=0.001, 150 µM; VEGF‑C: P=0.049, 
50 µM; P=0.044, 150 µM), whereas VEGF‑B was significantly 
upregulated in the oleic acid (P<0.05) groups (Fig. 6A and B).
Numerous factors modulate angiogenesis in cancer. The 
current study investigated the expression of several angio‑
genesis‑associated genes including chemokine (C‑C motif) 
ligand 2 (CCL2), Hypoxia inducible factor 1, α submit 
(HIF‑1α), high mobility group box 1 (HMGB1), and trans‑
forming growth factor‑β1 (TGF‑β1). CCL2 is recognized for 
its role in the inflammatory response and modulation of angio‑
genesis (27). HMGB1, a proinflammatory cytokine, is crucial 
for inflammation‑associated diseases and involved in cell 
apoptosis and angiogenesis (28). HIF‑1α, an oxygen balance 
regulator, regulates VEGF transcription and is involved in 
numerous cell functions, including angiogenesis (29). TGF‑β1, 
a multifunction factor for cells, has also been previously 
demonstrated to induce angiogenesis progression (30). In 
the present study, these four mRNA levels were significantly 
inhibited by 150 µM ximenynic acid compared with the vehicle 
control group (CCL2, P=0.016; TGF‑β1, P=0.004; HMGB1, 
P=0.007; HIF‑1α, P=0.044; Fig. 6C‑F). By contrast, oleic acid 
acid significantly promoted the expression of HMGB1 genes at 
50 µM (P=0.002), however did not show significant effects on 
TGF‑β1, CCL2 and HIF‑1α genes compared with the control 
group (Fig. 6C‑F).
Discussion
Ximenynic acid is one of main components of sandalwood seed 
fatty acids, and remains to be fully investigated. Sandalwood 
Figure 6. Expression variations of angiogenesis‑associated genes in HepG2 cells following fatty acids treatment. Following incubation with ximenynic acid or 
oleic acid for 72 h, the expression of angiogenesis‑associated genes including (A) VEGF‑B, (B) VEGF‑C, (C) CCL2, (D) TGF‑β1, (E) HMGB1 and (F) HIF‑1α 
were analysed by reverse transcription‑polymerase chain reaction. O50 and O150 groups were treated with oleic acid at 50 and 150 µM, respectively. X50 and 
X150 groups were treated with ximenynic acid at 50 and 150 µM, respectively. Data are presented as the mean ± standard deviation; n=3. *P<0.05 vs. the vehicle 
group. VEGF, vascular endothelial growth factor; CCL2, chemokine (C‑C motif) ligand 2; TGF‑β1, transforming growth factor‑β1; HMGB1, high mobility 
group box 1; HIF‑1α, hypoxia inducible factor‑1α.
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is widely used in perfume, artwork, furniture and for religious 
reasons, however, the sandalwood tree is a slow‑growing plant 
and requires decades or even centuries for full growth. For 
the sustainable development of the sandalwood industry, it the 
value of the sandalwood seed should be investigated.
Sandalwood seeds are rich in oil, and the main fatty acids 
of the oil are oleic acid and ximenynic acid. The structure of 
oleic acid is very similar to ximenynic acid, excluding a triple 
bond. The anti‑inflammatory and anti‑cancer properties of 
oleic acid are inferior compared with ximenynic acid, which 
suggests that the conjugated enyne structure of ximenynic 
acid is crucial for the medicinal properties. Thus, xime‑
nynic acid may be the key functional factor of sandalwood 
seed oil. In addition, numerous acetylenic fatty acids exert 
important pharmacological functions, including antibacte‑
rial (2), anti‑inflammatory (5) and anti‑cancer (10) activities. 
Ximenynic acid has been demonstrated to be anti‑bacterial (3) 
and anti‑inflammatory (5), whereas the anti‑cancer proper‑
ties remain unclear. In the current study MTT assay and 
flow cytometry results demonstrated the anti‑proliferative 
and apoptosis‑promoting activities of ximenynic acid on 
HepG2 cells. Western blotting and qPCR analysis revealed 
the suppressive effect of ximenynic acid on the expression of 
apoptosis‑ and angiogenesis‑associated factors. These suggest 
that the anti‑cancer activity of ximenynic acid is mediated by 
regulating cell cycle, apoptosis and angiogenesis pathways.
Ximenynic acid induced G1/G0 phase arrest in HepG2 cells 
and inhibited the expression of CCND3 and CCNE1 genes, and 
GCN5L2 protein. G1/G0 phase is the critical stage for DNA 
replication, therefore, arrest of cancer cells in G1/G0 phase 
may contribute to inhibition of cancer cell proliferation (31). 
D type‑cyclins (D1, D2, D3) are important for cell cycle 
progression, inducing the transition from G1 to S phase (32). It 
previously demonstrated that downregulation of cyclin D3 was 
correlated with cell cycle arrest and apoptosis (33). Cyclin E 
is the key factor of G1/S transition, and overexpression of 
cyclin E protein can induce tumorigenesis (34) and shorten 
the cell cycle (35). In addition, GCN5L2 was previously 
reported to promote G1/S transition and promote the expres‑
sion of cell cycle‑associated factors, including cyclin D3 (23) 
and cyclin E1 (36). The present study demonstrated that the 
protein levels of GCN5L2 were reduced by ximenynic acid. 
This suggests that the anti‑cancer activity of ximenynic acid 
is associated with histone acetylation via downregulation of 
GCN5L2 that inhibits cyclin expression to arrest cancer cells 
in G0/G1 phase.
Ximenynic acid induced HepG2 cell apoptosis and 
inhibited SIRT1 expression. SIRT1 has been previously 
reported to inhibit cellular senescence and suppress cell 
apoptosis (37). Overexpression of SIRT1 affects histone 
deacetylation and inhibits deacetylation of certain tumor 
repressor proteins, including p53 (38). The results of the 
present study demonstrated that ximenynic acid downregu‑
lates the expression of SIRT1 in a dose‑dependent manner. 
The progression of cancer is promoted by accumulation 
of epigenetic and genetic changes (39). Acetylation and 
methylation are post‑translational histone modifications 
that modulate transcriptional activity, DNA recombination 
and repair. The results of the present study suggest that the 
anti‑cancer activity of ximenynic acid may be mediated 
through the deacetylation or methylation of certain critical 
factors in tumor progression.
Ximenynic acid selectively inhibited COX‑1 expression, 
however it exhibited no effect on COX‑2. Typically, ximenynic 
acid has been previously used for anti‑inflammatory treatment 
and decreases the activity of COXs (4,5). It was previously 
reported that NSAIDs inhibit cancer cell growth by suppressing 
COX‑2 activity (40), but selective inhibition of COX‑1 may 
achieve the same effect (11,12). As a typical example, aspirin, a 
COX‑1 relative inhibitor, was demonstrated to be beneficial for 
inhibiting a wide variety of cancers (9). In addition, selective 
inhibition of COX‑1 expression induces apoptosis in certain 
types of cancer cells (41). The present study demonstrated that 
ximenynic acid did not alter the COX‑2 level, however had 
resulted in clear inhibition of COX‑1 expression. COX‑2 was 
increased following ximenynic acid treatment, however, the 
expression of COX‑1 was reduced. This indicates that ximenynic 
acid is a selectively inhibits COX‑1 expression. Ximenynic acid 
may suppress angiogenesis of HepG2 cells through inhibition 
of COX‑1 expression. Angiogenesis is involved in de novo 
generation of blood vessels, and is considered crucial for 
tumor growth and metastasis (42). Overexpression of COX‑1 
has previously been demonstrated to promote the expression of 
angiogenic growth factors (11). In the current study, ximenynic 
acid suppressed COX‑1 protein expression, and inhibited the 
gene expression of TGF‑β1, and HMGB1. As a multifunctional 
cytokine, TGF‑β1 has previously been revealed to induce 
angiogenesis (30) and be involved in the progression of angio‑
genesis induced by COX‑1 (43) or HMGB1 (44). In addition, 
overexpression of HMGB1 has been observed to induce prolif‑
eration of cancer cells and angiogenesis (28). Gene and protein 
expression of HIF‑1α is also affected by HMGB1 (45). This 
suggests that the anti‑cancer activity of ximenynic acid in the 
HepG2 cell line may be achieved through inhibiting angiogenic 
factors.
The anti‑cancer activity of ximenynic acid is predomi‑
nantly attributed to the inhibition of COX‑1, which may be 
Figure 7. The putative pathways of ximenynic acid‑induced anticancer 
activity. The anticancer activity of ximenynic acid may associate with cell 
cycle, angiogenesis and cell apoptosis pathways by inhibition of COX‑1, 
GCN5L2 and SIRT1 proteins, and COX‑1 may be the key factor of this 
pathway. GCN5L2, general control of amino acid synthesis yeast homolog 
like 2; COX,‑1 cyclooxygenase; SIRT1, silent information regulator T1; 
VEGF, vascular endothelial growth factor. 
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associated with histone acetylation modification (46,47). 
A previous report demonstrated that selective inhibition of 
COX‑1 could suppress angiogenesis (14) and induce G0/G1 
phase arrest of the cell cycle due to suppression of cyclin E, 
which is the key protein for G1/S transition (13). Further‑
more, inhibition of COX‑1 has previously been observed to 
induce apoptosis and activation of capspase‑3 (48). Addition‑
ally, ximenynic acid may affect the histone acetylation. The 
association between COX‑1, GCN5L2 and SIRT1 proteins 
remains unclear, however, the latter two are involved in 
histone acetylation. In addition, aspirin, a relative COX‑1 
inhibitor, has an enhanced anti‑carcinogenic activity when 
it was used in combination with a histone deacetylase 
inhibitor (49). Taken together, the results of the present study 
indicate that ximenynic acid may regulate the acetylation of 
histones to exert anti‑cancer and anti‑inflammatory activi‑
ties.
The anti‑cancer activity of ximenynic acid may be asso‑
ciated with the cell cycle, angiogenesis and cell apoptosis 
pathways. The putative pathways of ximenynic acid are 
presented in Fig. 7, and the anti‑cancer activity of ximenynic 
acid may be associated with the suppression of the expression 
of COX‑1, GCN5L2 and SIRT1 proteins, promotion of cell 
cycle arrest in G0/G1 phase through suppression cell cycle 
regulatory factors, blocking of angiogenesis by inhibiting 
the VEGF family, and the acceleration of cell apoptosis via 
caspase‑3 activation. In summary, ximenynic acid inhibited 
proliferation and induced apoptosis of HepG2 cells, altered 
cell cycle distribution and inhibited the expression of angio‑
genesis‑associated factors.
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